The duo will focus on developing and commercializing Nurix’s investigational Bruton’s Tyrosine Kinase degrader, bexobrutideg.

The Swiss drugmaker said it would pay Nurix $700 million upfront, while development costs would be split 60-40, with Roche ...

For the first time, a blood test has been added to the list of the American Cancer Society’s recommended screenings for ...

The American Cancer Society updated colorectal cancer screening guidelines, adding blood-based tests and reaffirming ...

Grail's multi-cancer blood test can find cancer — but there's still one big problem with how it works.

Many cancers, including pancreatic, ovarian, esophageal, and certain liver cancers, are often diagnosed at advanced stages ...

Shares of Legend Biotech rose more than 40% Tuesday—on pace for the stock's biggest percentage increase on record—after the ...

Shares for ADC Therapeutics fell more than 50% after a Phase 3 trial observed a death rate that at least one analyst believes ...

Scientists have identified a blood-based protein signature that can predict lung cancer risk more than five years before ...

Researchers at the Francis Crick Institute and University College London (UCL), funded by Cancer Research UK and the European Research Council (ERC), have identified a 14-protein signature in the ...

A newly identified "blood signature" may predict lung cancer risk more than five years before diagnosis, offering a potential ...